-
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
Source: Nasdaq GlobeNewswire / 12 Dec 2024 15:00:00 America/Chicago
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting.
The Combined Shareholders' Meeting was held on Wednesday December 11, 2024, at 9 a.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.
Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the general meeting.
All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 59th resolution, which had been the subject of a negative recommendation by the Board of Directors. The 59th resolution would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.
Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the report of the Board of Directors (Schedules 1 to 4, pages 27 and seq.).
Information on the results of the votes is detailed below:
- Total number of shares composing the share capital: 87 077 695
- Total number of shares with voting rights: 86 962 703
Ordinary part Extraordinary part Shareholders Shares Votes Shareholders Shares Votes
Shareholders present 2 13 000 13 000 2 13 000 13 000
Proxy to third parties 0 0 0 0 0 0
Proxy to the Chairman 111 4 701 495 4 770 465 111 4 701 495 4 770 465
Mail votes 72 64 628 619 76 624 677 72 64 628 619 76 624 677
TOTAL 185 69 343 114 81 408 142 185 69 343 114 81 408 142
Quorum 79,738 % 79,738 % VOTE RESULTS
Ordinary Resolutions
Resolution Result For Against Abstention Total number of votes cast Number of represented shares Proportion of represented share capital Non- voting votes Invalid votes Quorum Votes % Votes % Votes % 1 Adopted 81 065 229 99,58 % 341 425 0,42 % 1 488 - 81 406 654 69 343 114 79,633 % 0 0 79,738 % 2 Adopted 81 066 149 99,58 % 340 505 0,42 % 1 488 - 81 406 654 69 343 114 79,633 % 0 0 79,738 % 3 Adopted 64 373 078 99,40 % 386 537 0,60 % 16 648 527 - 64 759 615 69 343 114 79,633 % 0 0 79,738 % 4 Adopted 81 021 688 99,53 % 383 921 0,47 % 2 533 - 81 405 609 69 343 114 79,633 % 0 0 79,738 % VOTE RESULTS
Extraordinary Resolutions
Resolution Result For Against Abstention Total number of votes cast Number of represented shares Proportion of represented share capital Non- voting votes Invalid votes Quorum Votes % Votes % Votes % 5 Adopted 81 357 493 99,96 % 31 297 0,04 % 19 352 - 81 388 790 69 343 114 79,633 % 0 0 79,738 % 6 Adopted 73 651 642 99,99 % 10 853 0,01 % 2 730 107 - 73 662 495 64 327 574 73,873 % 5 015 540 0 78,498 % 7 Adopted 73 651 972 99,99 % 10 523 0,01 % 7 745 647 - 73 662 495 69 343 114 79,633 % 0 0 79,738 % 8 Adopted 72 649 419 99,99 % 10 523 0,01 % 1 267 546 - 72 659 942 64 073 710 73,582 % 7 480 654 0 78,432 % 9 Adopted 74 537 483 99,99 % 10 523 0,01 % 3 544 556 - 74 548 006 66 027 534 75,826 % 3 315 580 0 78,935 % 10 Adopted 75 120 718 99,99 % 10 883 0,01 % 1 267 921 - 75 131 601 64 334 494 73,881 % 5 008 620 0 78,500 % 11 Adopted 72 946 906 99,99 % 10 523 0,01 % 1 267 921 - 72 957 429 62 160 322 71,384 % 7 182 792 0 77,914 % 12 Adopted 78 507 669 99,99 % 10 883 0,01 % 1 267 521 - 78 518 552 67 721 045 77,770 % 1 622 069 0 79,353 % 13 Adopted 75 603 876 99,99 % 10 883 0,01 % 1 267 521 - 75 614 759 64 817 252 74,436 % 4 525 862 0 78,626 % 14 Adopted 79 586 996 99,99 % 10 523 0,01 % 1 267 521 - 79 597 519 68 800 012 79,009 % 543 102 0 79,611 % 15 Adopted 77 112 497 99,99 % 10 883 0,01 % 2 323 555 - 77 123 380 67 381 907 77,381 % 1 961 207 0 79,271 % 16 Adopted 77 109 342 99,98 % 14 038 0,02 % 3 228 728 - 77 123 380 68 287 080 78,420 % 1 056 034 0 79,489 % 17 Adopted 78 074 460 99,98 % 14 038 0,02 % 1 267 921 - 78 088 498 67 291 391 77,277 % 2 051 723 0 79,249 % 18 Adopted 76 008 147 99,99 % 10 523 0,01 % 1 267 921 - 76 018 670 65 221 563 74,900 % 4 121 551 0 78,730 % 19 Adopted 78 923 202 99,99 % 10 523 0,01 % 1 267 521 - 78 933 725 68 136 218 78,247 % 1 206 896 0 79,453 % 20 Adopted 79 828 350 99,99 % 10 523 0,01 % 1 267 546 - 79 838 873 69 041 391 79,287 % 301 723 0 79,668 % 21 Adopted 79 828 050 99,99 % 10 523 0,01 % 1 267 846 - 79 838 573 69 041 391 79,287 % 301 723 0 79,668 % 22 Adopted 79 526 627 99,99 % 10 522 0,01 % 1 267 546 - 79 537 149 68 739 667 78,940 % 603 447 0 79,597 % 23 Adopted 81 359 867 99,96 % 33 095 0,04 % 15 180 - 81 392 962 69 343 114 79,633 % 0 0 79,738 % 24 Adopted 71 582 912 99,98 % 11 523 0,02 % 5 634 249 - 71 594 435 65 163 656 74,833 % 4 179 458 0 78,715 % 25 Adopted 71 583 312 99,98 % 11 522 0,02 % 6 726 444 - 71 594 834 66 256 250 76,088 % 3 086 864 0 78,993 % 26 Adopted 71 583 312 99,98 % 11 522 0,02 % 9 416 262 - 71 594 834 68 946 068 79,177 % 397 046 0 79,645 % 27 Adopted 71 583 672 99,98 % 11 522 0,02 % 9 616 857 - 71 595 194 69 147 023 79,408 % 196 091 0 79,693 % 28 Adopted 73 651 045 99,98 % 11 522 0,02 % 2 730 035 - 73 662 567 64 327 574 73,873 % 5 015 540 0 78,498 % 29 Adopted 73 651 045 99,98 % 11 522 0,02 % 7 745 575 - 73 662 567 69 343 114 79,633 % 0 0 79,738 % 30 Adopted 78 506 742 99,99 % 11 522 0,01 % 1 267 809 - 78 518 264 67 721 045 77,770 % 1 622 069 0 79,353 % 31 Adopted 75 602 949 99,98 % 11 523 0,02 % 1 267 808 - 75 614 472 64 817 252 74,436 % 4 525 862 0 78,626 % 32 Adopted 80 129 171 99,99 % 11 522 0,01 % 1 267 449 - 80 140 693 69 343 114 79,633 % 0 0 79,738 % 33 Adopted 81 369 605 99,97 % 21 077 0,03 % 17 460 - 81 390 682 69 343 114 79,633 % 0 0 79,738 % 34 Adopted 72 648 517 99,98 % 11 547 0,02 % 1 267 424 - 72 660 064 64 073 710 73,582 % 7 480 654 0 78,432 % 35 Adopted 74 536 581 99,98 % 11 522 0,02 % 3 544 459 - 74 548 103 66 027 534 75,826 % 3 315 580 0 78,935 % 36 Adopted 75 120 191 99,98 % 11 523 0,02 % 1 267 808 - 75 131 714 64 334 494 73,881 % 5 008 620 0 78,500 % 37 Adopted 72 946 380 99,98 % 11 522 0,02 % 1 267 448 - 72 957 902 62 160 322 71,384 % 7 182 792 0 77,914 % 38 Adopted 78 506 742 99,99 % 11 522 0,01 % 1 267 809 - 78 518 264 67 721 045 77,770 % 1 622 069 0 79,353 % 39 Adopted 75 603 309 99,98 % 11 522 0,02 % 1 267 449 - 75 614 831 64 817 252 74,436 % 4 525 862 0 78,626 % 40 Adopted 79 586 070 99,99 % 11 522 0,01 % 1 267 448 - 79 597 592 68 800 012 79,009 % 543 102 0 79,611 % 41 Adopted 77 111 571 99,99 % 11 522 0,01 % 2 323 842 - 77 123 093 67 381 907 77,381 % 1 961 207 0 79,271 % 42 Adopted 77 111 570 99,99 % 11 523 0,01 % 3 229 015 - 77 123 093 68 287 080 78,420 % 1 056 034 0 79,489 % 43 Adopted 78 077 449 99,99 % 11 547 0,01 % 1 267 423 - 78 088 996 67 291 391 77,277 % 2 051 723 0 79,249 % 44 Adopted 76 007 621 99,98 % 11 522 0,02 % 1 267 448 - 76 019 143 65 221 563 74,900 % 4 121 551 0 78,730 % 45 Adopted 78 922 276 99,99 % 11 522 0,01 % 1 267 448 - 78 933 798 68 136 218 78,247 % 1 206 896 0 79,453 % 46 Adopted 79 827 089 99,99 % 11 522 0,01 % 1 267 808 - 79 838 611 69 041 391 79,287 % 301 723 0 79,668 % 47 Adopted 79 827 088 99,99 % 8 522 0,01 % 1 270 809 - 79 835 610 69 041 391 79,287 % 301 723 0 79,668 % 48 Adopted 79 525 724 99,99 % 11 523 0,01 % 1 267 448 - 79 537 247 68 739 667 78,940 % 603 447 0 79,597 % 49 Adopted 81 369 446 99,97 % 20 777 0,03 % 17 919 - 81 390 223 69 343 114 79,633 % 0 0 79,738 % 50 Adopted 71 583 672 99,98 % 11 523 0,02 % 5 633 489 - 71 595 195 65 163 656 74,833 % 4 179 458 0 78,715 % 51 Adopted 71 583 673 99,98 % 11 522 0,02 % 6 726 083 - 71 595 195 66 256 250 76,088 % 3 086 864 0 78,993 % 52 Adopted 71 583 673 99,98 % 11 522 0,02 % 9 415 901 - 71 595 195 68 946 068 79,177 % 397 046 0 79,645 % 53 Adopted 71 583 673 99,99 % 8 522 0,01 % 9 619 856 - 71 592 195 69 147 023 79,408 % 196 091 0 79,693 % 54 Adopted 73 651 045 99,98 % 11 523 0,02 % 2 730 034 - 73 662 568 64 327 574 73,873 % 5 015 540 0 78,498 % 55 Adopted 73 651 046 99,98 % 11 522 0,02 % 7 745 574 - 73 662 568 69 343 114 79,633 % 0 0 79,738 % 56 Adopted 75 603 340 99,98 % 11 492 0,02 % 1 267 448 - 75 614 832 64 817 252 74,436 % 4 525 862 0 78,626 % 57 Adopted 80 129 201 99,99 % 11 493 0,01 % 1 267 448 - 80 140 694 69 343 114 79,633 % 0 0 79,738 % 58 Adopted 81 020 280 99,54 % 372 859 0,46 % 15 003 - 81 393 139 69 343 114 79,633 % 0 0 79,738 % 59 Rejected 7 685 904 9,76 % 71 063 231 90,24 % 2 659 007 - 78 749 135 69 343 114 79,633 % 0 0 79,738 % 60 Adopted 75 436 351 92,67 % 5 970 263 7,33 % 1 528 - 81 406 614 69 343 114 79,633 % 0 0 79,738 % 61 Adopted 81 029 215 99,54 % 376 299 0,46 % 2 628 - 81 405 514 69 343 114 79,633 % 0 0 79,738 % 62 Adopted 81 014 251 99,53 % 379 238 0,47 % 14 653 - 81 393 489 69 343 114 79,633 % 0 0 79,738 % 63 Adopted 79 403 905 99,54 % 367 540 0,46 % 1 636 697 - 79 771 445 69 343 114 79,633 % 0 0 79,738 %
VOTE RESULTS
Ordinary Resolutions
Resolution Result For Against Abstention Total number of votes cast Number of represented shares Proportion of represented share capital Non- voting votes Invalid votes Quorum Votes % Votes % Votes % 64 Adopted 76 371 031 93,82 % 5 034 133 6,18 % 2 978 - 81 405 164 69 343 114 79,633 % 0 0 79,738 % 65 Adopted 72 500 044 99,51 % 359 596 0,49 % 8 548 502 - 72 859 640 69 343 114 79,633 % 0 0 79,738 % 66 Adopted 81 391 050 99,98 % 16 704 0,02 % 388 - 81 407 754 69 343 114 79,633 % 0 0 79,738 % About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.
Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.
Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
Contacts
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284
Important Notice
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements.
These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the expected benefit of having received Breakthrough Therapy Designation, including its impact on the development and review timeline of Inventiva’s product candidates, the potential development of and regulatory pathway for odiparcil, and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document for the year ended December 31, 2023, filed with the Autorité des Marchés Financiers on April 3, 2024 as amended on October 14, 2024, and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024, and the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.
Attachment
